Evaluation of the Effects of a Novel Dietary Microalgae Based Ingredient on Muscle Recovery and Endurance Capacity (PORPHY-ONE)

September 21, 2023 updated by: Microphyt

Evaluation of the Protective Effects of a Novel Dietary Microalgae Supplement (PeLiv) Following Exercise-induced Muscle Damage and Influence on Endurance Capacity After Prolonged Consumption

The purpose of this investigation is to examine the effects of consuming a new dietary microalgae based supplement vs. placebo on neuromuscular function, energy utilization, soreness, perceptual wellness, swelling, and markers of muscle damage and inflammation in healthy young men before and after an acute exercise-induced muscle damage protocol (downhill running), and influence on endurance capacity after prolonged consumption.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Orlando, Florida, United States, 32816
        • University of Central Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male participants
  • Healthy as assessed by Medical and activity history questionnaire (MHQ)
  • Recreationally active according to American College of Sports Medicine guidelines
  • Able to provide written and dated informed consent to participate in the study

Exclusion Criteria:

  • Untrained
  • Any response of "yes" on the PAR-Q+
  • Physical limitations preventing running, countermovement jump, and strength (peak isometric torque and peak isokinetic torque) assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo group
2 capsules of Maltodextrin per day
2 months of supplementation with a placebo (Maltodextrin)
Experimental: MicAlgae100
2 capsules per day containing 100mg of microalgae based ingredient
2 months of supplementation with an innovative microalgae based ingredient
Experimental: MicAlgae250
2 capsules per day containing 250mg of microalgae based ingredient
2 months of supplementation with an innovative microalgae based ingredient
Experimental: MicAlgae500
2 capsules per day containing 500mg of microalgae based ingredient
2 months of supplementation with an innovative microalgae based ingredient

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neuromuscular function
Time Frame: From 0 to week 4
isokinetic peak torque in Newton per meter (N/m)
From 0 to week 4

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Energy utilization (Oxygen consumption - VO2)
Time Frame: From 0 to week 4
Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis
From 0 to week 4
Energy utilization (Oxygen consumption - VO2)
Time Frame: From 0 to week 8
Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis
From 0 to week 8
Isokinetic neuromuscular function
Time Frame: From 0 to week 8
peak torque in Newton per meter (N/m)
From 0 to week 8
Isometric neuromuscular function
Time Frame: From 0 to week 8
peak torque in Newton per meter (N/m)
From 0 to week 8
Endurance capacity
Time Frame: From 0 to week 4
Maximal oxygen consumption (VO2max) determined during graded exercise test
From 0 to week 4
Endurance capacity
Time Frame: From 0 to week 8
Maximal oxygen consumption (VO2max) determined during graded exercise test
From 0 to week 8
Soreness and perceptual wellness
Time Frame: From 0 to week 4
Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol
From 0 to week 4
Soreness and perceptual wellness
Time Frame: From 0 to week 8
Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol
From 0 to week 8
Swelling - Muscle thickness (mm or cm)
Time Frame: From 0 to week 4
Evaluated using musculoskeletal ultrasound
From 0 to week 4
Swelling - overall thigh circumference (mm or cm)
Time Frame: From 0 to week 4
Evaluated using musculoskeletal ultrasound
From 0 to week 4
Creatine kinase (UI/I)
Time Frame: After 4 weeks of supplementation
Blood marker analyzis
After 4 weeks of supplementation
lactate dehydrogenase (U/L)
Time Frame: After 4 weeks of supplementation
Blood marker analyzis
After 4 weeks of supplementation
Myoglobin (ug/l)
Time Frame: After 4 weeks of supplementation
Blood marker analyzis
After 4 weeks of supplementation
Interleukin-6 (pg/ml)
Time Frame: After 4 weeks of supplementation
Blood marker analyzis - inflammation
After 4 weeks of supplementation
Tumor necrosis factor-α (ug/ml)
Time Frame: After 4 weeks of supplementation
Blood marker analyzis - inflammation
After 4 weeks of supplementation
C-reactive protein (mg/l)
Time Frame: After 4 weeks of supplementation
Blood marker analyzis - inflammation
After 4 weeks of supplementation
Isometric Neuromuscular function
Time Frame: From 0 to week 4
Peak torque in Newton per meter (N/m)
From 0 to week 4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: David Fukuda, PhD, University of Central Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2023

Primary Completion (Actual)

August 1, 2023

Study Completion (Actual)

August 18, 2023

Study Registration Dates

First Submitted

February 23, 2023

First Submitted That Met QC Criteria

March 6, 2023

First Posted (Actual)

March 8, 2023

Study Record Updates

Last Update Posted (Actual)

September 22, 2023

Last Update Submitted That Met QC Criteria

September 21, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY00004940

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe